Results 81 to 90 of about 13,388,853 (301)

STUDI IN SILICO POTENSI SENYAWA ALLIIN BAWANG PUTIH (Allium sativum) SEBAGAI INHIBITOR DPP-4 PADA DIABETES MELLITUS

Jurnal Ilmiah Medicamento, 2018
Diabetes mellitus (DM) merupakan penyakit gangguan metabolisme glukosa yang dicirikan dengan gangguan sekresi dan resistensi insulin. Jalur pengobatan DM baru pada sistem increatin dengan penghambatan terhadap DPP-4 telah dikembangkan dan terbukti ...
Martina Kurnia Rohmah
doaj   +5 more sources

Concomitant Use of DPP‐4 Inhibitors May Prevent the Development of Oxaliplatin‐Induced Peripheral Neuropathy: A Retrospective Cohort Study

Clinical and Translational Science
Oxaliplatin‐induced peripheral neuropathy (OIPN) causes numbness and pain in the limbs, often leading to interruption of chemotherapy and representing a significant clinical problem.
Yusuke Koura, Keisuke Mine, Shunsuke Fujita, Takehiro Kawashiri, Yusuke Mori, Mami Ueda, Risa Kaneko, Takeshi Hirota, Mayako Uchida, Daisuke Kobayashi   +9 more
doaj   +1 more source

Population Pharmacokinetic/Pharmacodynamic Analysis of the DPP-4 Inhibitor Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus

Journal of Pharmacy & Pharmaceutical Sciences, 2013
[Objectives] Linagliptin is a novel, highly selective and long acting DPP-4 inhibitor for the treatment of type 2 diabetes mellitus (T2DM). Linagliptin exhibits non-linear pharmacokinetics (PK) due to saturable binding to plasma and tissue DPP-4. The aim
Yusuke Tadayasu, Akiko Sarashina, Yasuhiro Tsuda, Shinji Tatami, Christian Friedrich, Silke Retlich, Alexander Staab, Mikihisa Takano   +7 more
doaj   +1 more source

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

, 2010
James E Foley1, Jens Jordan21Clinical Research and Development, Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA; 2Institute for Clinical Pharmacology, Hannover Medical School, Hannover, GermanyAbstract: Various factors may confound how
James E Foley, Jens Jordan
core  

Homologous tumor‐targeting biomimetic nanozyme for synergistic NIR‐II photothermal and chemodynamic therapy

BMEMat, EarlyView.
Studies reveal that a biomimetic nanoplatform based on a cancer cell membrane‐camouflaged Au‐MnOx nanozyme (Au‐MnOx@CCM) can achieve synergistic antitumor therapy by combining NIR‐II mediated PTT with enhanced CDT, offering a promising strategy for precise and efficient tumor therapy. Abstract The therapeutic potential of nanozyme‐mediated chemodynamic
Xiaonan Li, Siman Luo, Yucheng Zuo, Liheng Chen, Houjuan Zhu, Jing‐Yi Zhu, Wei Xue   +6 more
wiley   +1 more source

Association of DPP-4 inhibitors with respiratory and cardiovascular complications in patients with COPD: a nationwide cohort study

ERJ Open Research
Aims COPD is a comorbid condition often associated with type 2 diabetes (T2D) and cardiovascular diseases, but few studies have observed the impact of various antidiabetic drugs in patients with COPD and T2D.
Fu-Shun Yen, James Cheng-Chung Wei, Fu-Shun Ko, Yuhan Huang, Hei-Tung Yip, Fuu-Jen Tsai, Chii-Min Hwu, Chih-Cheng Hsu   +7 more
doaj   +1 more source

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from to

Therapeutic Advances in Chronic Disease, 2019
Dipeptidyl peptidase IV (DPP-4), an incretin glucagon-like peptide-1 (GLP-1) degrading enzyme, contains two forms and it can exert various physiological functions particular in controlling blood glucose through the action of GLP-1.
Shian-Ren Lin, Chia-Hsiang Chang, May-Jwan Tsai, Henrich Cheng, Jian-Chyi Chen, Max K. Leong, Ching-Feng Weng   +6 more
doaj   +1 more source

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes

, 2017
Plamen Kozlovski,1 Vaishali Bhosekar,2 James E Foley3 1Novartis Pharma AG, Basel, Switzerland; 2Novartis Healthcare Private Limited, Hyderabad, India; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Introduction: Dipeptidyl peptidase-4 (DPP ...
Bhosekar V, Foley JE, Kozlovski P
core  

Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.

, 2011
International audienceInhibition of dipeptidyl peptidase-4 (DPP-4) activity improves glucose homeostasis through a mode of action related to the stabilization of the active forms of DPP-4-sensitive hormones such as the incretins that enhance glucose ...
Pierre Cattan, Thierry Sulpice, Myriam Masseboeuf, Jens J. Holst, Waget, Aurélie, Holst, Jens Juul, Drucker, Daniel J, Magnan, Christophe, Rémy Burcelin, Sulpice, Thierry, Mélis Karaca, Adriano Maida, Castel, Julien, Maida, Adriano, Burcelin, Rémy, Mattieu Armanet, Cattan, Pierre, Julien Castel, Holst, Jens J, Celine Garret, Masseboeuf, Myriam, Armanet, Mattieu, Payros, Gaëlle, Cabou, Cendrine, Christophe Magnan, Cendrine Cabou, Aurélie Waget, Gaëlle Payros, Daniel J. Drucker, Garret, Celine, Karaca, Mélis   +30 more
core   +1 more source